Physician profile
Huma Qadir
NPI 1932466885
$5,209.91
in general payments reported to CMS, 2019-2025
23 companies · $13.62 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.04 · 2020: $474 · 2021: $2,166 · 2022: $1,026 · 2023: $843 · 2024: $650 · 2025: $13.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.51 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,070.93 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $668.54 | 2019-2024 | Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $536.88 | 2021-2022 | |
| Abbvie INC. | $422.96 | 2021-2024 | |
| Lundbeck LLC | $310.18 | 2020-2024 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $278.36 | 2020-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $247.48 | 2020-2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $245.05 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $230.61 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $226.57 | 2020-2024 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $162.87 | 2020-2023 | Ingrezza |
| Axsome Therapeutics, INC. | $157.31 | 2023-2024 | Auvelity |
| Alkermes, INC. | $141.07 | 2020-2024 | Lybalvi, Aristada, Aristada Initio |
| Adlon Therapeutics L.P. | $123.64 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.52 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $79.33 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $73.07 | 2021-2023 | Jornay Pm |
| Bausch Health US, LLC | $46.33 | 2021 | |
| Idorsia Pharmaceuticals US INC | $39.24 | 2023 | Quviviq |
| Tris Pharma INC | $21.82 | 2023 | Dyanavel Xr |
| Allergan, INC. | $19.98 | 2020 | |
| Almatica Pharma LLC | $15.31 | 2022 | |
| Alfasigma USA, INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Qadir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.